FDA Inspection 1222397 — Central Pennsylvania Blood Bank Headquarters
The FDA completed an inspection of Central Pennsylvania Blood Bank Headquarters on Oct 19, 2023 in Hummelstown, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Oct 19, 2023
- Fiscal Year
- 2024
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Hummelstown, PA (United States)